Stay updated with breaking news from Clinical Research Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today...
Patients newly treated with REL-1017 for up to one year experienced rapid, clinically meaningful, and sustained improvements in depressive symptoms and associated functional impairmentLong-term...
/PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today...
A study from the University of Michigan Rogel Cancer Center uncovers a new mechanism to explain why some prostate tumors switch from a common, treatable form to a more rare and aggressive form of prostate cancer.
A study uncovers a new mechanism to explain why some prostate tumors switch from a common, treatable form to a more rare and aggressive form of prostate cancer.